Abstract
Jade-1 is originally identified by the yeast two-hybrid system as a protein partner of von Hippel-Lindau (pVHL) tumor suppressor, a well-known renal tumor suppressor. In cellular signaling pathways, many upstream Jade-1 regulators, such as pVHL, CK1α, PC1, and NPHP4, can control its activity by stabilization, phosphorylation, and nuclear translocation. Numerous downstream effectors, including β-catenin, AKT, p21, and Bcl-2, are well modulated by Jade-1, which mainly regulates cell proliferation and apoptosis. Jade-1 is also deemed to be a candidate of transcriptional co-activator associated with histone acetyltransferase (HAT) activity. This review focuses on the anticancer role of Jade-1 in clear cell renal carcinoma and the inhibitory effect of Jade-1 on cystic renal diseases. This review aims to provide a basis of disease prevention or therapy.
Keywords: Jade-1, pVHL, renal cancer, renal cyst, HAT, β-catenin.
Current Molecular Medicine
Title:Jade-1: its structure, regulation and functions in the renal cancer.
Volume: 16 Issue: 1
Author(s): Y.-C. Zhang, W.-Q. Du, R.-Y. Zhang, J.-N. Zheng and D.-S. Pei
Affiliation:
Keywords: Jade-1, pVHL, renal cancer, renal cyst, HAT, β-catenin.
Abstract: Jade-1 is originally identified by the yeast two-hybrid system as a protein partner of von Hippel-Lindau (pVHL) tumor suppressor, a well-known renal tumor suppressor. In cellular signaling pathways, many upstream Jade-1 regulators, such as pVHL, CK1α, PC1, and NPHP4, can control its activity by stabilization, phosphorylation, and nuclear translocation. Numerous downstream effectors, including β-catenin, AKT, p21, and Bcl-2, are well modulated by Jade-1, which mainly regulates cell proliferation and apoptosis. Jade-1 is also deemed to be a candidate of transcriptional co-activator associated with histone acetyltransferase (HAT) activity. This review focuses on the anticancer role of Jade-1 in clear cell renal carcinoma and the inhibitory effect of Jade-1 on cystic renal diseases. This review aims to provide a basis of disease prevention or therapy.
Export Options
About this article
Cite this article as:
Zhang Y.-C., Du W.-Q., Zhang R.-Y., Zheng J.-N. and Pei D.-S., Jade-1: its structure, regulation and functions in the renal cancer., Current Molecular Medicine 2016; 16 (1) . https://dx.doi.org/10.2174/1566524016666151222144511
DOI https://dx.doi.org/10.2174/1566524016666151222144511 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-Infected Patients and Liver Transplantation: Who, When and Why
Current HIV Research Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect
Current Medicinal Chemistry A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Adult Neural Stem Cells: Response to Stroke Injury and Potential for Therapeutic Applications
Current Stem Cell Research & Therapy Collaborative and Defensive Fibroblasts in Tumor Progression and Therapy Resistance
Current Medicinal Chemistry Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets Angiogenesis Imaging Using 68Ga-RGD PET: Preliminary Report from Seoul National University Hospital
Current Medical Imaging Angiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology
Current Medicinal Chemistry Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Flavonoids Influence Epigenetic-Modifying Enzyme Activity: Structure-Function Relationships and the Therapeutic Potential for Cancer
Current Medicinal Chemistry The Interaction of Titanocene Y with Double-Stranded DNA: A Computational Study
Letters in Drug Design & Discovery Mesenchymal Epithelial Transition (MET): A Key Player in Chemotherapy Resistance and an Emerging Target for Potentiating Cancer Immunotherapy
Current Cancer Drug Targets The Urokinase Receptor in Hematopoietic Stem Cells Mobilization
Current Pharmaceutical Design Properties and Clinical Development of a Novel Coating Technology: The poly[bis(trifluoroethoxy)phosphazene]
Recent Patents on Drug Delivery & Formulation Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design Metabolite Identification in NMR-based Metabolomics
Current Metabolomics Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism
Current Drug Safety Sentinel Node in Endometrial Cancer: Rationale and Early Experience
Current Women`s Health Reviews